Business
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial.
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial.","length":503,"tagName":"p"},{"type":"text","content":""We are encouraged by our new data in hard-to-treat myelofibrosis patients where we observed spleen volume reduction, symptom improvement, hemoglobin stabilization and evidence of disease modification with selinexor monotherapy, addressing all four hallmarks of the disease," said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. "This new data adds to our growing body of evidence highlighting selinexor's potential in patients with myelofibrosis."","length":492,"tagName":"p","attribs":{}},{"type":"text","content":"The accepted abstract and data highlights are below.","length":52,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Abstract number: PS1821","length":23,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":23,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Title: A study to evaluate single-agent selinexor versus physician's choice in participants with previously treated myelofibrosis","length":133,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":133,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Date/Time: Saturday, June 14, 18:30-19:30 CEST","length":46,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":46,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Presenter: Alessandro Lucchesi, MD","length":34,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":34,"olType":false},{"type":"text","content":"Highlights ","length":10,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Data from the XPORT-MF-035 (NCT04562870) Phase 2, randomized, open-label trial of selinexor versus physician's-choice (PC) in hard-to-treat patients with heavily pre...